雌激素受体阳性乳腺癌中mTOR蛋白的表达及与内分泌辅助治疗预后的关系

Expression of m TOR Protein in Estrogen Receptor-Positive Breast Cancer and its Relationship with Prognosis of Endocrine Adjuvant Therapy

目的:研究雌激素受体阳性乳腺癌中m TOR蛋白的表达以及与内分泌辅助治疗预后的关系。方法:选取2010年6月到2011年8月我院收治的雌激素受体阳性乳腺癌且接受内分泌辅助治疗的患者110例,应用免疫组化法检测患者乳腺癌组织中的m TOR蛋白的表达,观察其与临床特征和预后的关系。结果:m TOR蛋白表达阳性者68例,m TOR蛋白表达阴性者42例,m TOR蛋白表达阳性者存在较多的组织学特征;m TOR蛋白表达阴性者无病中位生存期为(56.8±1.1)个月,显著优于m TOR蛋白表达阳性者的(32.8±2.1)个月,比较差异具有统计学意义(P<0.05);多因素分析显示,m TOR蛋白表达阳性者出现肿瘤复发转移的风险是m TOR蛋白表达阴性者的3.21倍,且是影响预后的独立性影响因子。结论:m TOR蛋白的表达阳性是雌激素受体阳性乳腺癌复发转移的独立因素,在临床上可以联合m TOR抑制剂来治疗。

Objective： To study the expression of mtor protein in estrogen receptor-positive breast cancer patients and its relationship with prognosis of endocrine adjuvant therapy. Methods： A total of 110 patients with estrogen receptor-positive breast cancer,who were admitted to Southern Hospital of Southern Medical University from June 2010 to August 2011, were selected and the m TOR protein expressions in their breast tissues were examined by immunohistochemistry method,and observed its relationship with clinical features and prognosis. Results： The expression of m TOR protein was positive in 68 cases;negative, in 42 cases. The patients with m TOR protein expression positive had more positive histologic features. The median disease-free survival time of m TOR protein expression negative patients was（56.8±1.1） months, significantly better than（32.8 ± 2.1） months in m TOR protein positive patients, the difference was statistically significant（P〈0.05）. Multivariate analysis showed that the risk of tumor recurrence and metastasis of m TOR protein expression positive patients,which was the independent influencing factor of prognosis, was 3.21 times that of m TOR protein expression negative patients. Conclusion： The m TOR protein expression positive is the independence factor of recurrence and metastasis of patients with estrogen receptor-positive breast cancer,which can be treated by being combined with m TOR inhibitor clinically.